Key Summary
- VPAG deadline extended to 14 November for pharma companies
- Firms must declare by deadline or remain in the 2024 scheme for 2026
- Extension allows more time amid global industry uncertainty
The Association of the British Pharmaceutical Industry (ABPI) and the government have extended Voluntary Scheme for Branded Medicines, Pricing, Access and Growth (VPAG) deadline for pharma companies.
The ABPI represents companies that research and develop new medicines, aiming to make the UK a global leader in medical innovation.
The new decision grants pharma companies an additional two-weeks to choose whether or not to leave the 2024 VPAG scheme.
The companies must issue a notice if their decision is to leave.
The change of deadline is aimed give companies adequate time to make a decision in the context of ongoing global uncertainty affecting the life sciences sector.
Earlier the companies were supposed to notify their choice before October 31, 2025.
However, the deadline has been extended to November 14.
The decision made on or before this day will be final.
Any firm that fails to notify their choice within the deadline will follow the 2024 VPAG scheme in 2026.
On the other hand, the ones who left will move to the Statutory Scheme for branded medicines.
A similar extension was implemented in 2024 in response to the planned timing for the publication of the statutory scheme consultation response as well.
However, this year’s deadline is completely separate and does not impact the future years of VPAG .
